Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.

Aggiungi a portafoglio

63,33+0,93 (+1,49%)

Alla chiusura: 4:00PM EST

I prezzi di scambio non provengono da tutti i mercati

Capitalizzazione	79,386B
Beta (5 anni mensile)	0,53
Rapporto PE (ttm)	62,89
EPS (ttm)	1,01
Prossima data utili	02 feb 2021 - 08 feb 2021
Rendimento e dividendo (forward)	2,72 (4,29%)
Data ex dividendo	14 dic 2020
Stima target 1A	72,46

Tutte

FX Empire
Gilead Sciences Upgrades 2020 Earnings Forecast on Strong Demand for Remdesivir
The U.S. drugmaker Gilead Sciences revised its full-year 2020 profit guidance as the second wave of coronavirus infections boosted the demand of Remdesivir, an antiviral agent that scientists initially designed to treat Ebola, also, beneficial for COVID-19 treatment.
FX Empire
Gilead Sciences Shares Rise 6% After U.S. FDA Approves Remdesivir for COVID-19 Treatment; Target Price $75
Gilead Sciences said that the U.S. Food and Drug Administration has approved the antiviral drug remdesivir for the COVID-19 treatment, sending its shares up about 6% in pre-market on Friday.
FX Empire
Gilead Sciences to Acquire Immunomedics for $21 Billion; Target Price $75
Gilead Sciences Inc, an American biopharmaceutical company that researches, develops and commercializes drugs, announced to acquire a pharmaceutical company Immunomedics Inc for $21 billion or $88.00 per share in cash, a move that will help strengthen its drugs portfolio for cancer.